Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant

Herzer K, Papadopoulos-Kohn A, Walker A, Achterfeld A, Paul A, Canbay A, et al. Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant. Digestion. 2015;91(4):326-333.

Publication Type:

Journal Article

Authors:

Herzer, K.; Papadopoulos-Kohn, A.; Walker, A.; Achterfeld, A.; Paul, A.; Canbay, A.; Timm, J.; Gerken, G.

Source:

Digestion, Volume 91, Issue 4, p.326-333 (2015)

Keywords:

adverse effects, Anemia, Gastroenterology, Germany, HCV, hepatitis, Hepatitis C, Immunosuppression, Infection, Laboratories, Liver, Liver Transplantation, methods, Patients, Recurrence, Ribavirin, simeprevir, Survival, transplantation, treatment, Universities, Viral Load, Viremia

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25999053

Export Citation:
RIS Format
Top